Form 4: NewAmsterdam Pharma Co N.V. Executive Granted Stock Options Following Appointment as Chief Business Officer

Juliette Berangere Audet, Chief Business Officer of NewAmsterdam Pharma Co N.V., received stock options for 250,000 ordinary shares following her appointment.

Summary

• Juliette Berangere Audet, previously a director, has been appointed as the Chief Business Officer (CBO) of NewAmsterdam Pharma Co N.V.
• Effective April 1, 2024, Audet resigned from the board of directors in light of her new role as CBO.
• In connection with her appointment, Audet was granted an option to purchase 250,000 ordinary shares at an exercise price of $21.37.
• 25% of the shares underlying the option will vest on April 1, 2025, with the remaining shares vesting monthly over the subsequent three years, contingent upon continued service.

Sentiment

Score: 7

Explanation: The document reflects a positive development with the appointment of a key executive and the granting of stock options, indicating confidence in the company's future prospects. It is a routine filing, but the appointment itself is a positive signal.

Positives

• The appointment of a CBO suggests a focus on business development and strategic growth for NewAmsterdam Pharma Co N.V.
• The vesting schedule incentivizes the CBO to remain with the company for the long term.

Future Outlook

The document does not contain explicit forward-looking statements, but the appointment of a CBO and the associated stock option grant suggest a focus on future business development and growth.

Industry Context

Executive compensation packages, including stock options, are common in the pharmaceutical industry to attract and retain talent. The size and vesting schedule of the option grant are likely benchmarked against industry standards for similar roles and companies.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation in the pharmaceutical industry, used to align executive interests with shareholder value.
• Comparable companies like Madrigal Pharmaceuticals or Viking Therapeutics also utilize stock options as part of their executive compensation packages.
• The vesting schedule of the options is typical, with a multi-year vesting period to incentivize long-term commitment.

Management Changes

Stakeholder Impact

• Shareholders may view the appointment of a CBO and the associated stock option grant as a positive sign, indicating a focus on growth and value creation.
• Employees may be positively impacted by the addition of a CBO, potentially leading to improved business strategies and opportunities.

Key Dates